Incisive Genetics

Incisive Genetics is a Canadian biotechnology company based in Vancouver, British Columbia, focused on developing non-viral, precision gene editing therapeutics for genetic diseases. The company was founded as a spinout from the University of British Columbia's Centre for Molecular Medicine and Therapeutics, building on more than two decades of research into Huntington's disease (HD). Its scientific leadership has studied the genetics, pathogenesis, and clinical progression of HD, and the company's mission is to redefine in vivo gene editing by delivering functional genome editing machinery directly to affected tissues. The company's lead program, IG-HD01, is a first-in-class investigational therapeutic that combines a pre-formed CRISPR ribonucleoprotein (RNP) complex with Incisive Genetics' proprietary lipid nanoparticle (LNP) delivery platform. Unlike single-shot viral approaches, this LNP-based system allows for adjustable, repeatable dosing to directly and safely target the brain regions most affected by Huntington's disease. IG-HD01 enables direct, allele-selective excision of the disease-causing portions of the mutant HTT gene while preserving normal HTT function, addressing the full spectrum of known pathogenic mechanisms in Huntington's disease. Incisive Genetics positions its proprietary LNP/RNP delivery platform as a transformative technology for genetic medicine beyond Huntington's disease, enabling additional programs and partnership opportunities. The company is privately held and is advancing from preclinical development toward human trials, with a leadership team bringing expertise across neurology, gene editing, clinical development, and operational execution.

Incisive Genetics was founded as a spinout from the University of British Columbia's Centre for Molecular Medicine and Therapeutics. Its origins are deeply rooted in Huntington's disease research; for more than two decades, its scientific leadership has studied the genetics, pathogenesis, and clinical progression of HD. While the causative mutation in the HTT gene has been known since 1993, delivering gene editing safely and effectively inside the human body remained a major hurdle. The company recognized that the future of gene editing would depend not only on powerful editing enzymes but on the ability to deliver them in their active form. This insight led to the development of its proprietary lipid nanoparticle platform capable of encapsulating and delivering pre-formed ribonucleoprotein (RNP) complexes in vivo. The company is based in Vancouver, Canada, and is advancing its lead program IG-HD01 from preclinical development toward human trials.

• Founded as a spinout from the University of British Columbia's Centre for Molecular Medicine and Therapeutics.

• Developed proprietary lipid nanoparticle platform for in vivo delivery of pre-formed RNP complexes.

• Lead program IG-HD01 advanced as a first-in-class investigational therapeutic for Huntington's disease.

Non-viral, allele-selective gene editing for genetic diseases, with a proprietary LNP/RNP delivery platform enabling adjustable, repeatable dosing.

• IG-HD01

  First-in-class investigational therapeutic combining a pre-formed CRISPR ribonucleoprotein (RNP) complex with a proprietary lipid nanoparticle (LNP) delivery platform for allele-selective excision of mutant HTT.

• LNP/RNP delivery platform

  Proprietary non-viral delivery system enabling adjustable, repeatable dosing and large cargo capacity for in vivo gene editing.

1. 1Home - Incisive Geneticsincisivegenetics.com
2. 2About Us - Incisive Geneticsincisivegenetics.com
3. 3Science & Pipeline - Incisive Geneticsincisivegenetics.com
4. 4Incisive Genetics (Canada) - Wikidatawikidata.org